| Tracey Jane Spangenberg, RPH | |
|
9300 Campus Point, Dept Pharmacy, La Jolla, CA 92037-7727 | |
| (858) 657-5006 | |
| Not Available |
| Full Name | Tracey Jane Spangenberg |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 9300 Campus Point, La Jolla, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366150880 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 45260 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tracey Jane Spangenberg, RPH 9300 Campus Point, Dept Pharmacy, La Jolla, CA 92037-7727 Ph: (858) 657-5006 | Tracey Jane Spangenberg, RPH 9300 Campus Point, Dept Pharmacy, La Jolla, CA 92037-7727 Ph: (858) 657-5006 |
News Archive
Children and adolescents who refuse to attend school should not be given doctors' sick notes. In the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[4]), child and adolescent psychiatrist Martin Knollmann and colleagues explain the causes of school avoidance and describe measures to tackle the problem.
Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.
A pooled analysis of the global RESOLUTE clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic, Inc., across a wide variety of patient and lesion types.
A new study by researchers from Rush University Medical Center and Tufts University School of Medicine using mice indicate that a child's memory and the severity of learning disorders may be affected by what his or her mother did when she was a child.
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
› Verified 5 days ago
Amy Waller, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7544 Girard Ave, La Jolla, CA 92037 Phone: 858-454-0932 Fax: 858-454-8518 | |
Arthur Shen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9350 Campus Point Dr, La Jolla, CA 92037 Phone: 858-657-8512 Fax: 858-657-8621 | |
Pablina Jones, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3855 Health Sciences Dr # 845, La Jolla, CA 92093 Phone: 858-822-6091 Fax: 858-822-6092 | |
Hue Nhan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7525 Eads Ave, La Jolla, CA 92037 Phone: 858-551-8698 | |
Alexander Kent Yee, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9300 Campus Point Dr, La Jolla, CA 92037 Phone: 858-249-5682 | |
Paricheh Azimi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9300 Campus Point Dr, La Jolla, CA 92037 Phone: 858-249-6181 | |
Ashley Ta, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9300 Campus Point Dr, La Jolla, CA 92037 Phone: 858-657-7000 |